BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11912398)

  • 1. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia.
    Hochberg DA; Basillote JB; Armenakas NA; Vasovic L; Shevchuk M; Pareek G; Fracchia JA
    J Urol; 2002 Apr; 167(4):1731-3. PubMed ID: 11912398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia.
    Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S
    Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients.
    Pareek G; Shevchuk M; Armenakas NA; Vasovic L; Hochberg DA; Basillote JB; Fracchia JA
    J Urol; 2003 Jan; 169(1):20-3. PubMed ID: 12478093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transurethral Resection of Prostate and Bleeding: A Prospective, Randomized, Double-Blind Placebo-Controlled Trial to See the Efficacy of Short-Term Use of Finasteride and Dutasteride on Operative Blood Loss and Prostatic Microvessel Density.
    Bansal A; Arora A
    J Endourol; 2017 Sep; 31(9):910-917. PubMed ID: 28650680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride.
    Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Rodríguez-Vallejo JM; González-Esteban J; Miranda G; Torrubia F
    Prostate; 1999 Jul; 40(2):83-8. PubMed ID: 10386468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of benign prostatic hyperplasia and finasteride therapy on prostatic blood flow in dogs.
    Angrimani DSR; Silvestrini GR; Brito MM; Abreu RA; Almeida LL; Vannucchi CI
    Theriogenology; 2018 Jul; 114():103-108. PubMed ID: 29605575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Two Weeks Preoperative Finasteride Therapy in Reducing Prostate Vascularity.
    Khwaja MA; Nawaz G; Muhammad S; Jamil MI; Faisal M; Akhter S
    J Coll Physicians Surg Pak; 2016 Mar; 26(3):213-5. PubMed ID: 26975954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride.
    Foley SJ; Soloman LZ; Wedderburn AW; Kashif KM; Summerton D; Basketter V; Holmes SA
    J Urol; 2000 Feb; 163(2):496-8. PubMed ID: 10647664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
    Sutton MT; Yingling M; Vyas A; Atiemo H; Borkowski A; Jacobs SC; Kyprianou N
    Prostate; 2006 Aug; 66(11):1194-202. PubMed ID: 16652387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks.
    Donohue JF; Hayne D; Karnik U; Thomas DR; Foster MC
    BJU Int; 2005 Dec; 96(9):1319-22. PubMed ID: 16287453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia.
    Carlin BI; Bodner DR; Spirnak JP; Resnick MI
    Prostate; 1997 May; 31(3):180-2. PubMed ID: 9167770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study.
    Kaya C; Ozyurek M; Turkeri LN
    Int J Urol; 2005 Feb; 12(2):194-8. PubMed ID: 15733115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.
    Kearney MC; Bingham J; Bergland R; Meade-D'Alisera P; Puchner PJ
    J Urol; 2002 Jun; 167(6):2489-91. PubMed ID: 11992064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.
    Montironi R; Valli M; Fabris G
    J Clin Pathol; 1996 Apr; 49(4):324-8. PubMed ID: 8655710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of correlation between prostate-specific antigen density and prostatic shrinkage in response to finasteride therapy.
    Kirschenbaum A; Pacheco E; Schuval BJ; Levine AC
    World J Urol; 1996; 14(6):360-2. PubMed ID: 8986036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.
    Lekas AG; Lazaris AC; Chrisofos M; Papatsoris AG; Lappas D; Patsouris E; Deliveliotis C
    Urology; 2006 Aug; 68(2):436-41. PubMed ID: 16904480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA
    Arch Esp Urol; 1999 Apr; 52(3):201-8. PubMed ID: 10371735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report.
    Puchner PJ; Miller MI
    J Urol; 1995 Nov; 154(5):1779-82. PubMed ID: 7563345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia.
    Kaplan SA; Holtgrewe HL; Bruskewitz R; Saltzman B; Mobley D; Narayan P; Lund RH; Weiner S; Wells G; Cook TJ; Meehan A; Waldstreicher J;
    Urology; 2001 Jun; 57(6):1073-7. PubMed ID: 11377309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.